Back to all studies
🦴
Phase 2
Pain Management
in-person
A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)
Sponsored by Merck Sharp & Dohme LLC
Compensation
$500–$2,500
Duration
3 months
Location
Nationwide
About this study
Researchers are looking for new ways to treat rheumatoid arthritis (RA). Methotrexate (MTX) is a standard (usual) treatment for RA. However, MTX and other current treatments may not work well to treat RA symptoms for many people. This study will help find out if a study medicine called tulisokibart can treat symptoms of active RA in people who are taking MTX. In this study, researchers will look at different doses of tulisokibart. Researchers want to learn if at least one of the study doses o…
Who can participate
- • Adults aged 18–80
- • All genders welcome
- • Diagnosed with or experiencing arthritis, rheumatoid
- • Able to attend in-person clinic visits
What's included
- • Compensation up to $2,500
- • All study-related medical care at no cost
- • Lab work, screenings, and physician consultations
- • Study medication or treatment provided
IRB-approved study. Free to apply. Your information is kept confidential.
Ready to Find a Paid Study?
Join over 100,000 people who have been matched with clinical studies. It's free, fast, and could change your life.